Skip to main content

Lantern Pharma Inc.

corporate_fare Company Profile

Lantern Pharma Inc.

LTRN·NASDAQ·Life Sciences·CIK 0001763950

We are an artificial intelligence (A.I.) focused company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Our development portfolio includes three clinical stage oncology focused product candidates and consists of small molecules that others have tried, but failed, to develop into an approved commercialized drug, as well as new compounds that we are developing with the assistance of our proprietary A.I. platform and our biomarker driven approach. Our A.I. platform, known as RADR®, currently includes more than 200 billion data points, and uses big data analytics (combining molecular data, drug efficacy data, data from historical studies, data from scientific literature, phenotypic data from trials and publications, and mechanistic pathway data) and machine learning to rapidly uncover biologically relevant genomic signatures correlated to drug response, and then identify the cancer patients that we believe may benefit most from our compounds. This data-driven, genomically-targeted and biomarker-driven approach allows us to pursue a transformational drug development strategy that identifies, rescues or develops, and advances potential small molecule drug candidates at what we believe is a fraction of the time and cost associated with traditional cancer drug development. On average, our newly developed drug programs have been advanced from initial A.I. insights to first-in-human clinical trials in 2-3 years and at approximately $1.0-$2.5 million per program. We have active clinical programs for our three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple important cancer indications, including both solid tumors and blood cancers. We have established a wholly-owned subsidiary, Starlight Therapeutics, to focus exclusively on the clinical development of our promising opportunities for central nervous system ("CNS") and brain cancers, many of which have no effective treatment options. We are also advancing an antibody-drug conjugate ("ADC") program focused on developing highly specific ADCs with highly potent drug-payloads. In January 2026, we introduced withZeta.ai - a generative AI platform purpose-built to empower researchers and clinicians to accelerate rare cancer research and drug development, dramatically improve research quality, and reduce R&D costs.

Lantern Pharma Inc. (NASDAQ:LTRN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 31 items for LTRN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-18, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 10/10, with 10 rated 8 or above. Recent SEC coverage for LTRN spans 8-K, 10-Q, PRE 14A, 424B5.

Recent high-impact activity:

  • Lantern Pharma Q3: $7.6M Cash, Going-Concern Warning, Interim CEO After Sharma Exit
  • Lantern Pharma Q3: $7.6M Cash, Going-Concern Doubt, $2M Settlement Accrual
  • Lantern Pharma 10-Q: Second Nasdaq Deficiency, CEO Exit and $2M Settlement Accrual
  • Lantern Pharma Seeks Approval to Double Authorized Shares and Issue 3.67M Warrant Shares
  • Taiwan Approvals Open Next Stage of HARMONIC Trial for LP-300 in EGFR-Mutant NSCLC

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$17.12M
Diluted EPS
-$1.57
Op. Cash Flow
-$15.68M
Free Cash Flow
-$15.68M
Operating Income
-$17.98M
Cash & Equivalents
$4.42M
Debt / Equity
0.00×
Shares Outstanding
11.25M sh
Source: 10-K · filed 2026-04-30 · accession 0001493152-26-019713

Short Interest & Short Volume

2.68 days to cover

FINRA reported short interest of 924,479 shares in LTRN as of the October 30, 2026 settlement, a 137.9% increase from the prior period — about 2.7 days to cover at its recent average daily volume. On November 20, 2026, 70.1% of LTRN volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)924,479 shares as of October 30, 2026
Change vs prior period▲ 137.9%
Days to cover2.68 at avg daily volume of 345,314
Daily short volume (FINRA facilities)70.1% of 172,585 shares on November 20, 2026
5-day average short volume48.0%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for LTRN, detected from its recent SEC filings · based on capital-structure filings through 2026-09-30.

1 recent capital raise1 shelf registration

Registration for Resale · Potential Dilution and Market Overhang

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with L →
$0.23 -6.12% today
52-week range · as of 2026-11-18 $0.23 – $4.34
Market cap
$3.89M
Volume
238.5K (1.0× avg)
3-mo avg 246.6K
Live data · 2026-11-21 20:55 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed LTRN - Latest Insights

LTRN
Nov 18, 2026, 8:00 AM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $0.3724
Real-time Price: $0.230 info
Change: -$0.1424 (-38%) info
Market Cap: $3.892M info
LTRN
Nov 18, 2026, 7:35 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.3724
Real-time Price: $0.230 info
Change: -$0.1424 (-38%) info
Market Cap: $3.892M info
LTRN
Nov 17, 2026, 4:25 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.365
Real-time Price: $0.230 info
Change: -$0.135 (-37%) info
Market Cap: $3.892M info
LTRN
Oct 08, 2026, 4:05 PM EDT
Filing Type: PRE 14A
Importance Score:
7
Price at Filing: $0.830
Real-time Price: $0.230 info
Change: -$0.600 (-72%) info
Market Cap: $3.892M info
LTRN
Oct 07, 2026, 8:31 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $0.950
Real-time Price: $0.230 info
Change: -$0.720 (-76%) info
Market Cap: $3.892M info
LTRN
Oct 01, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.00
Real-time Price: $0.230 info
Change: -$0.770 (-77%) info
Market Cap: $3.892M info
LTRN
Sep 30, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.01
Real-time Price: $0.230 info
Change: -$0.780 (-77%) info
Market Cap: $3.892M info
LTRN
Sep 30, 2026, 9:29 AM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $1.09
Real-time Price: $0.230 info
Change: -$0.855 (-79%) info
Market Cap: $3.892M info
LTRN
Sep 29, 2026, 8:08 AM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $1.05
Real-time Price: $0.230 info
Change: -$0.820 (-78%) info
Market Cap: $3.892M info
LTRN
Sep 22, 2026, 7:45 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $1.48
Real-time Price: $0.230 info
Change: -$1.25 (-84%) info
Market Cap: $3.892M info
LTRN
Aug 14, 2026, 7:35 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.55
Real-time Price: $0.230 info
Change: -$2.32 (-91%) info
Market Cap: $3.892M info
LTRN
Aug 14, 2026, 7:30 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.55
Real-time Price: $0.230 info
Change: -$2.32 (-91%) info
Market Cap: $3.892M info
LTRN
Aug 14, 2026, 7:30 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $2.60
Real-time Price: $0.230 info
Change: -$2.37 (-91%) info
Market Cap: $3.892M info
LTRN
Aug 03, 2026, 5:24 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.65
Real-time Price: $0.230 info
Change: -$2.42 (-91%) info
Market Cap: $3.892M info
LTRN
Jul 28, 2026, 7:45 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $2.84
Real-time Price: $0.230 info
Change: -$2.61 (-92%) info
Market Cap: $3.892M info
LTRN
Jun 12, 2026, 4:30 PM EDT
Filing Type: S-1
Importance Score:
7
Price at Filing: $3.88
Real-time Price: $0.230 info
Change: -$3.65 (-94%) info
Market Cap: $3.892M info
LTRN
Jun 02, 2026, 8:16 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $3.84
Real-time Price: $0.230 info
Change: -$3.61 (-94%) info
Market Cap: $3.892M info
LTRN
Jun 01, 2026, 7:40 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.51
Real-time Price: $0.230 info
Change: -$3.28 (-93%) info
Market Cap: $3.892M info
LTRN
May 19, 2026, 7:36 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $3.12
Real-time Price: $0.230 info
Change: -$2.89 (-93%) info
Market Cap: $3.892M info
LTRN
May 15, 2026, 4:07 PM EDT
Filing Type: 8-K
Importance Score:
10
Price at Filing: $2.81
Real-time Price: $0.230 info
Change: -$2.58 (-92%) info
Market Cap: $3.892M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets